Promising treatment option and improved survival rates for patients with ovarian, bre
 

Olaparib, an experimental twice-daily oral cancer drug, produces an overall tumor response rate of 26 percent in several advanced cancers associated with BRCA1 and BRCA2 mutations, according to new...

More...